NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT® (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib. Although PFS was numerically higher in patients treated with temsirolimus, the difference was not statistically significant. Ove

NEW YORK--(BUSINESS WIRE)--New data will be presented on targeted cancer treatments from the Pfizer Oncology portfolio across three key therapeutic categories, including tumors of the kidney, lung and hematologic malignancies, at the Annual Meeting of the American Society of Clinical Oncology in Chicago, IL, from June 1-5. Approximately 100 abstracts featuring Pfizer’s cancer treatments and investigational compounds across 20 cancer types will be presented during the meeting. “We are very proud

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with David Simmons, President and General Manager, Emerging Markets and Established Products, at the Bank of America Merrill Lynch 2012 Healthcare Conference on Thursday, May 17, 2012 at 8:00 a.m. Pacific Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Bank of America Merrill Lynch 2012 Healthcare Conference” link in Tab 2 of the I

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted 8-2 to recommend approval of the investigational agent tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The Committee’s recommendation will be considered by the FDA in its review of the New Drug Application (NDA) for tofacitinib. The FDA has provided an anticipated Prescription Dru

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced new data presented at the 165th Annual Meeting of the American Psychiatric Association (APA) in Philadelphia on PRISTIQ® (desvenlafaxine) Extended Release Tablets 50 mg/day for the treatment of major depressive disorder (MDD) in adults,1 including a long-term relapse prevention study. These new data, and data from a study in peri- and post-menopausal women with MDD, add to the existing efficacy and safety profile of PRISTIQ for the tre

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 randomized withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy (pDPN) did not meet its primary efficacy endpoint, change in endpoint mean pain score relative to baseline. The study, A0081242, is a Phase 3b Multicenter, Double-Blind, Randomized Withdrawal Efficacy and Safety Study of Pregabalin in the Treatment of Patients with Inadequately Tre

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has stopped a Phase 3 clinical trial of Lyrica (pregabalin) in patients with neuropathic pain associated with HIV neuropathy, a form of nerve damage characterized by burning pain usually beginning in the feet. The decision follows review of a planned interim analysis of the study by the trial’s external Data Monitoring Committee (E-DMC). There were no safety concerns raised in the E-DMC review of the interim data. The pro

NEW YORK & CARMIEL, Israel--(BUSINESS WIRE)--Pfizer Inc.(NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease. ELELYSO is the first FDA-approved plant cell-based ERT for Gaucher disease. It is also the first approved pla

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE):   ($ in millions, except per share amounts)     First-Quarter 2012   2011(4)   Change Reported Revenues $ 15,405 $ 16,502 (7 %) Adjusted Income(1) 4,432 4,808 (8 %) Adjusted Diluted EPS(1) 0.58 0.60 (3 %) Reported Net Income(2) 1,794 2,222 (19 %) Reported Diluted EPS(2) 0.24 0.28 (14 %)                       See end of text prior to tables for notes. Pfizer Inc. (NYSE: PFE) today reported financial results for first-quarter 2012. First-quarter

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today issued the following statement regarding a pending court case in Utah: "The parties to Brigham Young University and Dr. Daniel Simmons v. Pfizer Inc. et al., a matter in the United States Court for the District of Utah, Central Division, announce that they have reached an amicable settlement on confidential terms. As part of the resolution, BYU will establish the Dan Simmons Chair in recognition of Dr. Simmons' lifelong work and contributions towards